Does elevated C-peptide indicate increased endogenous insulin secretion?

Elevated C-peptide is generally a credible marker of endogenous pancreatic insulin output, but its meaning in hyperglycemia depends on glucose stimulus, renal clearance, and disease stage.

Clinical interpretation

• C-peptide and insulin are released by β cells in approximately equimolar amounts during proinsulin processing. Because C-peptide largely avoids variable first-pass hepatic insulin extraction, an elevated circulating concentration usually supports greater endogenous insulin secretion rather than exposure to injected insulin.
• With concurrent hyperglycemia—particularly glucose above about 7.8 mmol/L (140 mg/dL)—a high C-peptide is consistent with glucose-stimulated insulin secretion and compensatory hyperinsulinemia. Reduced insulin sensitivity commonly evokes this higher secretion early in dysglycemia, while later β-cell failure may result in lower secretion despite persistent hyperglycemia.
• This pattern supports, rather than establishes, insulin resistance. It cannot by itself distinguish compensation from other contributors to high circulating C-peptide.

Mechanistic considerations

• Hyperglycemia directly stimulates β-cell insulin/C-peptide release. Therefore, a nonfasting or post-meal result reflects both underlying β-cell capacity and the immediate glucose stimulus.
• In clamp-based cross-sectional observations, higher C-peptide/endogenous secretion has been associated with poorer muscle insulin sensitivity, greater liver fat, and reduced insulin clearance. Obese insulin-resistant adolescents likewise showed higher basal and clamp C-peptide, consistent with early islet up-regulation.

Practical interpretation

• Renal function is essential: C-peptide is substantially kidney-cleared, so impaired renal clearance can elevate it independently of secretion and may mask insulin deficiency.
• Interpret C-peptide with simultaneous glucose, fasting versus fed/stimulated status, kidney function, medications, and diabetes duration. A single value is not a direct measurement of insulin sensitivity or a precise secretion rate.

Bottom line

• Elevated C-peptide with hyperglycemia supports preserved/increased endogenous insulin secretion compatible with compensatory hyperinsulinemia from reduced insulin sensitivity, but does not diagnose insulin resistance—especially without accounting for renal function and sampling context.